Eton Pharmaceuticals (ETON) investor relations material

Executive summary

• Achieved record Q3 2025 revenue of $22.5 million, up 129% year-over-year and 19th consecutive quarter of sequential product revenue growth, driven by ALKINDI SPRINKLE, Carglumic Acid, INCRELEX, and GALZIN.

• INCRELEX was the largest revenue contributor, with patient count stable and relaunch exceeding expectations; GALZIN launch surpassed year-end patient targets.

• Generated $12 million in operating cash flow and ended the quarter with $37.1 million in cash, supporting future growth and acquisitions.

• Adjusted EBITDA reached $2.9 million, impacted by non-recurring INCRELEX ex-U.S. transition costs; GAAP net loss was $1.9 million, and non-GAAP net income was $1.5 million.

• ET-600 NDA accepted by FDA with a February 2026 PDUFA date; label expansion efforts for KHINDIVI and INCRELEX are progressing.

Financial highlights

• Q3 2025 revenue was $22.5 million, up 118%–129% year-over-year, including $0.9 million from non-recurring INCRELEX inventory sales and $2.4 million from an initial INCRELEX loading order.

• Adjusted gross profit was $10.2 million (45% margin), down from 64% in the prior year due to INCRELEX ex-U.S. transition costs; core U.S. business gross margin exceeded 70%.

• R&D expenses rose to $1.1 million, mainly from ET-700 and ET-800 development; adjusted G&A was $6.9 million, up from $4.3 million year-over-year.

• Adjusted EBITDA was $2.9 million, up from $2.0 million year-over-year; non-GAAP net income was $1.5 million, with a GAAP net loss of $1.9 million.

• Cash and cash equivalents at quarter-end were $37.1 million, with $12 million in operating cash flow and working capital of $27.8 million.

Outlook and guidance

• Expects continued sequential U.S. product sales growth in Q4, though total product sales may be flat or slightly down due to non-recurring INCRELEX revenue.

• Fourth-quarter adjusted gross margin expected to be approximately 70%, with long-term gross margin targeted to exceed 75% by 2028.

• Anticipates strong revenue growth in 2026 from core products and new launches, including ET-600, with more detailed guidance to be provided with Q4 results.

• Management expects current cash and product revenues to fund operations for at least the next twelve months; additional financing may be needed if growth or spending outpaces projections.

• Plans to initiate ET-700 pilot study and KHINDIVI bioequivalence study in early 2026.